Vaginal Neoplasms: Clinical Trials

18 trials for Vaginal Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 3 unknown, 2 active not recruiting, 1 recruiting. 18 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 318Completed 12, Unknown 3, Active not recruiting 2, Recruiting 1

Follow Vaginal Neoplasms: new trials by email Literature Review of Vaginal Neoplasms trials Research Report on Vaginal Neoplasms

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 - Human Papillomavirus Infection
Phase 3Active not recruitingBeijing Health Guard Biotechnology, Inc27502022-03-232022-12-27
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years - HPV Infections, Cervical Cancer Stage IIa
Phase 3UnknownShanghai Bovax Biotechnology Co., Ltd.13482021-09-152024-04-17
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
9-valent HPV vaccine - HPV Infections, Cervical Cancer
Phase 3UnknownShanghai Bovax Biotechnology Co., Ltd.12002021-05-282024-04-17
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9 - HPV Infections, Cervical Cancer
Phase 3CompletedShanghai Bovax Biotechnology Co., Ltd.12002020-09-192023-11-24
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL® - Cervical Cancer, Vulvar Cancer
Phase 3CompletedShanghai Bovax Biotechnology Co., Ltd.16802020-05-282022-02-25
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL® - Cervical Cancer, Vulvar Cancer
Phase 3RecruitingShanghai Bovax Biotechnology Co., Ltd.80002020-04-282024-06-07
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
9vHPV vaccine - Papillomavirus Infections, Uterine Cervical Neoplasms
Phase 3CompletedMerck Sharp & Dohme LLC2012018-06-292020-02-25
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
V503 - Cervical Cancer, Vulvar Cancer
Phase 3CompletedMerck Sharp & Dohme LLC12122017-09-202019-11-21
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)4502016-05-102026-11-13
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
prasterone, placebo - Breast Cancer, Gynecologic Cancer
Phase 3CompletedAlliance for Clinical Trials in Oncology4642011-07-012019-02-07
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™), Placebo - Papillomavirus Infections
Phase 3CompletedMerck Sharp & Dohme LLC2502011-03-212018-11-14
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
V503, Placebo to V503 - Cervical Cancers, Vulvar Cancers
Phase 3CompletedMerck Sharp & Dohme LLC9242010-02-242018-11-27
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
V503 - Cervical Cancers, Vulvar Cancer
Phase 3CompletedMerck Sharp & Dohme LLC30742009-08-272022-10-03
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment - Bladder Cancer, Cervical Cancer
Phase 3UnknownRoyal Marsden NHS Foundation Trust752009-01-012011-07-15
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Fentanyl sublingual spray, Placebo - Cancer
Phase 3CompletedINSYS Therapeutics Inc1302007-10-012014-03-05
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Comparator: GARDASIL, Experimental: V503 - Cervical Cancer, Vulvar Cancer
Phase 3CompletedMerck Sharp & Dohme LLC148402007-09-242018-11-27
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
octreotide acetate, placebo, radiation - Cervical Cancer, Colorectal Cancer
Phase 3CompletedAlliance for Clinical Trials in Oncology1302002-04-012016-07-13
Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer
infection prophylaxis and management, management of therapy complications, surgical procedure - Cervical Cancer, Endometrial Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC2141998-02-012012-07-11

Narrower conditions

Uterine Cervical Neoplasms (18)  ·  Vulvar Neoplasms (14)  ·  Condylomata Acuminata (11)  ·  Papillomavirus Infections (9)  ·  Endometrial Neoplasms (5)  ·  Carcinoma, Ovarian Epithelial (3)  ·  Fallopian Tube Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Sarcoma (3)  ·  Anus Neoplasms (2)  ·  Breast Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Rectal Neoplasms (2)

Broader conditions

Female Urogenital Diseases (18)  ·  Female Urogenital Diseases and Pregnancy Complications (18)  ·  Genital Diseases (18)  ·  Genital Diseases, Female (18)  ·  Genital Neoplasms, Female (18)  ·  Neoplasms by Site (18)  ·  Urogenital Diseases (18)  ·  Urogenital Neoplasms (18)  ·  Uterine Cervical Diseases (18)  ·  Uterine Diseases (18)  ·  Uterine Neoplasms (18)  ·  Vaginal Diseases (18)  ·  Neoplasms (17)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Pathologic Processes (14)

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (3)  ·  Radiation (2)  ·  Vaccines, Synthetic (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)  ·  Brachytherapy (1)  ·  Cisplatin (1)  ·  Congresses as Topic (1)  ·  Dehydroepiandrosterone (1)  ·  Fentanyl (1)  ·  Octreotide (1)  ·  Papillomavirus Vaccines (1)  ·  Platinum (1)  ·  Radiotherapy (1)  ·  Radiotherapy, Intensity-Modulated (1)

Sponsors

Merck Sharp & Dohme LLC (6)  ·  Shanghai Bovax Biotechnology Co., Ltd. (5)  ·  Alliance for Clinical Trials in Oncology (2)  ·  Beijing Health Guard Biotechnology, Inc (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  INSYS Therapeutics Inc (1)  ·  National Cancer Institute (NCI) (1)  ·  Royal Marsden NHS Foundation Trust (1)

Countries

China (6)  ·  United States (3)  ·  Austria (2)  ·  Belgium (2)  ·  Germany (2)  ·  Italy (2)  ·  Spain (2)  ·  Canada (1)  ·  Finland (1)  ·  France (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Puerto Rico (1)  ·  United Kingdom (1)  ·  Vietnam (1)

Top investigators

Charles A Leath (1)  ·  Debra Barton, RN, PhD, AOCN, FAAN (1)  ·  James A. Martenson, MD (1)  ·  John R. Yarnold, MD, FRCR (1)  ·  Larry Dillaha, MD (1)  ·  Sergio L. Pecorelli, MD (1)  ·  Ting Huang (1)  ·  Yongjiang Liu, Bachelor (1)

Results publications

PMID 27422279, PMID 29211620, PMID 29269325, PMID 29767739, PMID 17466514, PMID 18768432, PMID 22480131, PMID 25278227, PMID 25693011, PMID 25749310, PMID 25912208, PMID 25912475, PMID 26086587, PMID 26101366, PMID 26366475, PMID 26411885, PMID 27020837, PMID 28789851, PMID 28886907, PMID 29868473, PMID 30982556, PMID 31681600, PMID 32659510, PMID 33326342, PMID 33676783, PMID 33844623, PMID 37667847, PMID 41166720

NIH funding

2009 (1), 2017 (1), U10CA180868 (1)